Neuromyelitis Optica Spectrum Disorder | Executive Insights | US/EU5 | 2021
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic neuroinflammatory disorder that can lead to blindness and paralysis. Most patients have a relapsing form of the disease, leading to progressively worsening disability. Three therapies have been approved in the markets under study to treat NMOSD: Alexion Pharmaceuticals’ Soliris (eculizumab), Roche / Chugai / Genentech’s Enspryng (satralizumab), and Horizon Therapeutics’ Uplinza (inebilizumab). However, their use is constrained by safety concerns and high cost. Thus, off-label therapies such as rituximab, corticosteroids, or immunosuppressive therapy are often used, particularly in early lines of treatment, for both acute and long-term management of NMOSD. While the need for additional therapies is critical, improvements in diagnostics and disease understanding are also essential to facilitate advances in the treatment and management of NMOSD.
QUESTIONS ANSWERED
- What is the diagnosed prevalence of NMOSD in the United States and Europe, and how is the diagnosis made?
- How do approved NMOSD therapies (Soliris, Uplinza, and Enspryng) fit into the treatment algorithm for NMOSD? What are the advantages and disadvantages of these drugs?
- What are the key areas of unmet need and opportunity in the management of NMOSD?
- What is the state of the pipeline of NMOSD drugs, and what influence will emerging therapies have on the future NMOSD market?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States, EU4, United Kingdom
Primary Research: 12 KOL interviews in October 2021
Key Companies Covered: Alexion Pharmaceuticals, Horizon Therapeutics, Roche / Chugai / Genentech
Key Drugs Covered: Enspryng, Soliris, rituximab (Rituxan, biosimilars), Ultomiris, Uplizna, 9 preclinical and Phase I assets.
